bioMerieux released its Q4 17 trading results wherein sales were in line with our estimates. Revenue at CER came in at +8.9% on the back of double-digit growth in the clinical applications segment (+10.4%; accounts for c.81% of Q4 17 sales). Within the segment, the growth momentum accelerated in the molecular biology business (+40.4%; accounts for c.22% of Q4 17 sales) as an earlier start to the flu season boosted growth for FilmArray (+c.50%; particularly reagents for the respiratory panel).
24 Jan 2018
Led by an earlier flu season, bioMerieux ends FY17 ahead of guidance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Led by an earlier flu season, bioMerieux ends FY17 ahead of guidance
bioMerieux released its Q4 17 trading results wherein sales were in line with our estimates. Revenue at CER came in at +8.9% on the back of double-digit growth in the clinical applications segment (+10.4%; accounts for c.81% of Q4 17 sales). Within the segment, the growth momentum accelerated in the molecular biology business (+40.4%; accounts for c.22% of Q4 17 sales) as an earlier start to the flu season boosted growth for FilmArray (+c.50%; particularly reagents for the respiratory panel).